PF-Atlas › Clinical Trials › NCT03068234

Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis

Pirfenidone · Phase 2

Registry ID
NCT03068234
Phase
Phase 2
Status
Unknown
Drug / intervention
Pirfenidone
Sponsor
RenJi Hospital
Start
2017-05
Enrollment
72
Locations
1

About this trial

This study is to evaluate the efficacy and safety of an antifibrotic agent, pirfenidone as treatment of systemic sclerosis. The primary outcome of this study is improvement of skin fibrosis.

View NCT03068234 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT03068234 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.